Answers are grounded in this paper and cite their sources.
Background Alzheimer's disease (AD) features amyloid-β (Aβ) deposition and tau pathology, with microglial dysfunction and neuroinflammation increasingly implicated. Soluble triggering receptor expressed on myeloid cells-2 (sTREM2) and progranulin (PGRN) regulate microglial function and lysosomal homeostasis, but their dynamics across the AD continuum remain unclear. Objective To investigate cerebrospinal fluid (CSF) sTREM2 and PGRN in the early diagnosis and progression monitoring of AD, and their associations with Aβ pathology and other biomarkers. Methods Data were from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Based on CSF Aβ 42 and Clinical Dementia Rating (CDR) scores, subjects were categorized into Aβ−CN (n = 196), Aβ+CN (n = 101), Aβ+MCI (n = 378), and Aβ+AD (n = 96). Baseline demographics, neuropsychological assessments, imaging indices, and CSF biomarkers were compared. Spearman correlation, ROC curve analysis, and linear mixed-effects models (n = 255) were used. Results Baseline CSF sTREM2 was lower in Aβ+CN than Aβ−CN. PGRN was lower in Aβ+CN and Aβ+MCI than Aβ−CN. Over 2 years, sTREM2 increased most in Aβ+MCI and moderately in Aβ+CN, while PGRN declined in Aβ−CN, Aβ+MCI, and Aβ+AD. Both biomarkers correlated with CSF tau and p-tau in Aβ+ individuals. Conclusions Baseline CSF sTREM2 and PGRN have limited cross-sectional diagnostic value for AD. However, their longitudinal trajectories raise the possibility that they may reflect the microglia-lysosome axis. Combined biomarker strategies and multi-targeted therapeutic interventions warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: